In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B (cas 1397-89-3) formulations: Heated Amphotericin B (cas 1397-89-3) and Amphotericin B (cas 1397-89-3)-loaded microemulsion

Add time:09/03/2019    Source:sciencedirect.com

Amphotericin B (cas 1397-89-3) (AmB) is effective against visceral leishmaniasis (VL), but the renal toxicity of the conventional form, mixed micelles with deoxycholate (M-AmB), is often dose-limiting, while the less toxic lipid-based formulations such as AmBisome® are very expensive. Two different strategies to improve the therapeutic index of AmB with inexpensive ingredients were evaluated on this work: (i) the heat treatment of the commercial formulation (H-AmB) and (ii) the preparation of an AmB-loaded microemulsion (ME-AmB). M-AmB was heated to 70 °C for 20 min. The resulting product was characterized by UV spectrophotometry and circular dichroism, showing super-aggregates formation. ME-AmB was prepared from phosphate buffer pH 7.4, Tween 80®, Lipoid S100® and Mygliol 812® with AmB at 5 mg/mL. The droplet size, measured by dynamic light scattering, was about 40 nm and transmission electron microscopy confirmed a spherical shape. Rheological analysis showed low viscosity and Newtonian behavior. All the formulations were active in vitro and in vivo against Leishmania donovani (LV9). A selectivity index (CC50 on RAW/IC50 on LV9) higher than 10 was observed for ME-AmB, H-AmB and AmBisome®. Furthermore, no important in vivo toxicity was observed for all the samples. The in-vivo efficacy of the formulations after IV administration was evaluated in Balb/C mice infected with LV9 (three doses of 1 mg/kg AmB) and no significant difference was observed between H-AmB, M-AmB, ME-AmB and AmBisome®. In conclusion, these two inexpensive alternative formulations for AmB showing good efficacy and selectivity for Leishmania donovani merit further investigation.

We also recommend Trading Suppliers and Manufacturers of Amphotericin B (cas 1397-89-3). Pls Click Website Link as below: cas 1397-89-3 suppliers

Prev:Case ReportFungemia due to Fusarium solani under low-dose liposomal Amphotericin B (cas 1397-89-3) in a patient after cord blood transplantation☆
Next:Release of different Amphotericin B (cas 1397-89-3) formulations from PMMA bone cements and their activity against Candida biofilm)